Thomas J. Carmona-LaSalle

Thomas J. Carmona-LaSalle

Auto-generated profile, based on publicly available information

Thomas J. Carmona-LaSalle

Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
YLYijia Li
Yijia Li
ASAlexis M. Schneider
Alexis M. Schneider
AMArnav Mehta
Arnav Mehta
MSMoshe Sade-Feldman
Moshe Sade-Feldman
KKKyle R. Kays
Kyle R. Kays
JLJonathan Z. Li
Jonathan Z. Li
BACKGROUND. SARS-CoV-2 plasma viremia has been associated with severe disease and death in COVID-19 in small-scale cohort studies. The mechanisms behind this association remain elusive. METHODS. We evaluated the relationship between SARS-CoV-2 viremia, disease outcome, and inflammatory and proteomic profiles in a cohort of COVID-19 emergency department participants. SARS-CoV-2 viral load was measured using a quantitative reverse transcription PCR–based platform. Proteomic data were generated with Proximity Extension Assay using the Olink platform. RESULTS. This study included 300 participants with nucleic acid test–confirmed COVID-19. Plasma SARS-CoV-2 viremia levels at the time of presentation predicted adverse disease outcomes, with an adjusted OR of 10.6 (95% CI 4.4–25.5, P < 0.001) for severe disease (mechanical ventilation and/or 28-day mortality) and 3.9 (95% CI 1.5–10.1, P = 0.006) for 28-day mortality. Proteomic analyses revealed prominent proteomic pathways associated with SARS-CoV-2 viremia, including upregulation of SARS-CoV-2 entry factors (ACE2, CTSL, FURIN), heightened markers of tissue damage to the lungs, gastrointestinal tract, and endothelium/vasculature, and alterations in coagulation pathways. CONCLUSION. These results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes. FUNDING. Mark and Lisa Schwartz; the National Institutes of Health (U19AI082630); the American Lung Association; the Executive Committee on Research at Massachusetts General Hospital; the Chan Zuckerberg Initiative; Arthur, Sandra, and Sarah Irving for the David P. Ryan, MD, Endowed Chair in Cancer Research; an EMBO Long-Term Fellowship (ALTF 486-2018); a Cancer Research Institute/Bristol Myers Squibb Fellowship (CRI2993); the Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH awards UL1TR001102 and UL1TR002541-01); and by the Harvard University Center for AIDS Research (National Institute of Allergy and Infectious Diseases, 5P30AI060354).

15 October 2021 in Science Immunology
Verified
Journal Article
Open access
PKPaulina Kaplonek
Paulina Kaplonek
CWChuangqi Wang
Chuangqi Wang
YBYannic Bartsch
Yannic Bartsch
SFStephanie Fischinger
Stephanie Fischinger
MGMatthew J. Gorman
Matthew J. Gorman
GAGalit Alter
Galit Alter
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral immunity after COVID-19.

26 May 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TLThomas LaSalle
Thomas LaSalle
EAEmily E Austin
Emily E Austin
GRGrant Rigney
Grant Rigney
EWEric Wehrenberg-Klee
Eric Wehrenberg-Klee
SNSarah Nesti
Sarah Nesti
UMUmar Mahmood
Umar Mahmood
Background Cancer immunotherapy research is expanding to include a more robust understanding of the mechanisms of treatment response and resistance. Identification of drivers of pro-tumor and anti-tumor immunity during treatment offers new strategies for effective alternative or combination immunotherapies. Currently, tissue or blood samples are collected and analyzed, then dichotomized based on clinical end points that may occur months or years after tissue is collected. While overall survival is ultimately the desired clinical outcome, this dichotomization fails to incorporate the nuances that may occur during an anti-tumor response. By failing to directly measure immune activation at the time of sampling, tumors may be misclassified and potentially obscure important biological information. Non-invasive techniques, such as positron emission tomography (PET), allow for global and quantitative measurements of cancer specific processes and are widely used clinically to help manage disease. Methods We have previously developed a novel PET agent that can non-invasively quantify granzyme B release in tumors and have demonstrated its ability to predict response to checkpoint inhibitor therapy in multiple murine models of cancer. Here, we used the quantitative measurement of granzyme B release as a direct and time-matched marker of immune cell activation in order to determine immune cell types and cytokines that correlate with effective checkpoint inhibitor therapy in both tumors and tumor-draining lymph nodes. Results Through PET imaging, we were able to successfully distinguish distinct microenvironments, based on tumor type, which influenced immune cell subpopulations and cytokine release. Although each tumor was marked by functionally distinct pathways of immune cell activation and inflammation, they also shared commonalities that ultimately resulted in granzyme B release and tumor killing. Conclusions These results suggest that discrete tumor immune microenvironments can be identified in both responsive and non-responsive tumors and offers strategic targets for intervention to overcome checkpoint inhibitor resistance.

22 February 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JCJee-Eun Choi
Jee-Eun Choi
CSCarlos Sebastian
Carlos Sebastian
CFChristina M. Ferrer
Christina M. Ferrer
CLCaroline A. Lewis
Caroline A. Lewis
MSMoshe Sade-Feldman
Moshe Sade-Feldman
RMRaul Mostoslavsky
Raul Mostoslavsky

15 February 2022 in Cell Reports Medicine
Verified
Journal Article
Open access
SFSamuel S. Freeman
Samuel S. Freeman
MSMoshe Sade-Feldman
Moshe Sade-Feldman
JKJaegil Kim
Jaegil Kim
CSChip Stewart
Chip Stewart
AGAnna L.K. Gonye
Anna L.K. Gonye
NHNir Hacohen
Nir Hacohen
Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve survival prediction. However, integrating immune/tumor-intrinsic features using data from a single assay (DNA/RNA) remains underexplored. Here, we analyze whole-exome and bulk RNA sequencing of tumors from new and published cohorts of 189 and 178 patients with melanoma receiving CPB, respectively. Using DNA, we calculate T cell and B cell burdens (TCB/BCB) from rearranged TCR/Ig sequences and find that patients with TMBhigh and TCBhigh or BCBhigh have improved outcomes compared to other patients. By combining pairs of immune- and tumor-expressed genes, we identify three gene pairs associated with response and survival, which validate in independent cohorts. The top model includes lymphocyte-expressed MAP4K1 and tumor-expressed TBX3. Overall, RNA or DNA-based models combining immune and tumor measures improve predictions of melanoma CPB outcomes.

13 May 2022 in Science Advances
Verified
Journal Article
Open access
MSMarcello Stanzione
Marcello Stanzione
JZJun Zhong
Jun Zhong
EWEdmond Wong
Edmond Wong
TLThomas J. LaSalle
Thomas J. LaSalle
JWJillian F. Wise
Jillian F. Wise
BDBenjamin J. Drapkin
Benjamin J. Drapkin
In small cell lung cancer (SCLC), acquired resistance to DNA-damaging therapy is challenging to study because rebiopsy is rarely performed. We used patient-derived xenograft models, established before therapy and after progression, to dissect acquired resistance to olaparib plus temozolomide (OT), a promising experimental therapy for relapsed SCLC. These pairs of serial models reveal alterations in both cell cycle kinetics and DNA replication and demonstrate both inter- and intratumoral heterogeneity in mechanisms of resistance. In one model pair, up-regulation of translesion DNA synthesis (TLS) enabled tolerance of OT-induced damage during DNA replication. TLS inhibitors restored sensitivity to OT both in vitro and in vivo, and similar synergistic effects were seen in additional SCLC cell lines. This represents the first described mechanism of acquired resistance to DNA damage in a patient with SCLC and highlights the potential of the serial model approach to investigate and overcome resistance to therapy in SCLC.